Screening

Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference

Retrieved on: 
Thursday, April 29, 2021

b'Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2021 Healthcare Conference.\nGuardant Health\xe2\x80\x99s management is scheduled to participate in a fireside chat on Wednesday, May 12 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.

Key Points: 
  • b'Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2021 Healthcare Conference.\nGuardant Health\xe2\x80\x99s management is scheduled to participate in a fireside chat on Wednesday, May 12 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.
  • The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum.
  • Guardant Health has commercially launched liquid biopsy-based Guardant360\xc2\xae, Guardant360 CDx, and GuardantOMNI\xc2\xae tests for advanced stage cancer patients, and Guardant Reveal\xe2\x84\xa2 test for early-stage cancer patients.
  • These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.\n'

Helio Health and National Cancer Center Awarded Grant from Ministry of Science and Technology to Evaluate Helio Liver Test in Real-World Screening Scenario in China

Retrieved on: 
Wednesday, April 28, 2021

The prospective and blinded study will measure the sensitivity and specificity of the Helio Liver Test compared with current standards of care for the detection of liver cancer, in approximately 3,000 subjects in China.

Key Points: 
  • The prospective and blinded study will measure the sensitivity and specificity of the Helio Liver Test compared with current standards of care for the detection of liver cancer, in approximately 3,000 subjects in China.
  • Results showed that the Helio Liver Test produced 88.7% sensitivity in early-stage HCC, while sensitivity for AFP, a well-known marker for liver cancer, alone was 57.5%.
  • The company\'s mission is to simplify cancer screening so lives can be saved by detecting cancer earlier.
  • Available at: https://seer.cancer.gov/statfacts/html/livibd.html [accessed March 8, 2021]\nView original content to download multimedia: http://www.prnewswire.com/news-releases/helio-health-and-national-cancer...\n'

Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People

Retrieved on: 
Wednesday, April 28, 2021

The study showed the non-invasive Cologuard test had high sensitivity in detecting colorectal cancer and large pre-cancerous lesions making it a strong candidate for increasing the screening options available for AN people.5\n"My earlier research showed that Cologuard is an effective screening test in Alaska Native people," Redwood said.

Key Points: 
  • The study showed the non-invasive Cologuard test had high sensitivity in detecting colorectal cancer and large pre-cancerous lesions making it a strong candidate for increasing the screening options available for AN people.5\n"My earlier research showed that Cologuard is an effective screening test in Alaska Native people," Redwood said.
  • "\nEach strategy reduced costs and increased QALYs in comparison with no screening, with Cologuard outperforming FIT and colonoscopy screening in all adherence scenarios.
  • Cost-effectiveness of multitarget stool DNA testing vs colonoscopy or fecal immunochemical testing for colorectal cancer screening in Alaska Native people.
  • Cologuard performance in repeat testing has not been evaluated.\nThe Cologuard test result should be interpreted with caution.

LogicBio announces clinical and corporate updates

Retrieved on: 
Wednesday, April 28, 2021

As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

Key Points: 
  • As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
  • "With COVID-19 restrictions being lifted in some U.S.states, additional clinical trial sites have recently been activated and have begun recruiting and screening patients.
  • "\n"We expect to enroll our first patient in the SUNRISE trial by mid-year 2021, which represents a slight delay from our earlier communications," said Frederic Chereau, president and chief executive officer of LogicBio.
  • "We are also pleased to report that we have pre-identified enough patients to fully enroll SUNRISE, assuming a certain number of screening failures.

Global Prenatal Screening Tests (In Vitro Diagnostics) Market Report 2020: Analysis and Forecast Model with COVID-19 Market Impact 2015-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 26, 2021

b'Key Inclusions of the market model are:\nInsightful review of the key industry trends.\nAnnualized total Prenatal Screening tests market revenue by segment and market outlooks from 2015-2030.\nGranular data on total procedures, units, average selling prices and market values by segment.\nQualitative market specific information is available with global trends further broken down into regional trends.

Key Points: 
  • b'Key Inclusions of the market model are:\nInsightful review of the key industry trends.\nAnnualized total Prenatal Screening tests market revenue by segment and market outlooks from 2015-2030.\nGranular data on total procedures, units, average selling prices and market values by segment.\nQualitative market specific information is available with global trends further broken down into regional trends.
  • In addition, analysts provide unique country specific insights on the market.\nSWOT analysis for Prenatal Screening tests market.\nCompetitive dynamics insights and trends provided for Prenatal Screening tests market.\nDrive the understanding of the market by getting the veritable big picture including an overview of the healthcare system.
  • In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.\nCountry specific overview of the healthcare system.\nCountry specific medtech regulatory landscape.\nCMO executives who must have deep understanding of the Prenatal Screening tests marketplace to make strategic planning and investment decisions.\nSourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.\nPrivate equity investors that need a deeper understanding of the market to identify and value potential investment targets.\nUnderstand the impact of COVID-19 on Prenatal Screening tests market.\nDevelop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.\nDevelop business strategies by understanding the trends shaping and driving Prenatal Screening tests market.\nDrive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Prenatal Screening tests market in the future.\nFormulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.\nIdentify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.\nTrack device sales in the global and country-specific Prenatal Screening tests market from 2015-2030.\nOrganize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005650/en/\n'

Corporate Screening Selected as Exclusive Background Screening Supplier for Premier SURPASS Purchasing Program

Retrieved on: 
Monday, April 26, 2021

b'CLEVELAND, April 26, 2021 /PRNewswire/ --Corporate Screening Services, Inc., a leading employment background screening provider, today announced that it has been awarded a category-exclusive, national group purchasing agreement with Premier Inc.\'s SURPASS highly committed purchasing program (Synergizing for Unparalleled Results in Procurement and Strategic Sourcing).\nSURPASS members now have access to best-in-class screening solutions, proactive service & relationship-focused support.\nFor more than 30 years, Corporate Screening has served as the background screening provider of choice for the country\'s leading healthcare organizations.

Key Points: 
  • b'CLEVELAND, April 26, 2021 /PRNewswire/ --Corporate Screening Services, Inc., a leading employment background screening provider, today announced that it has been awarded a category-exclusive, national group purchasing agreement with Premier Inc.\'s SURPASS highly committed purchasing program (Synergizing for Unparalleled Results in Procurement and Strategic Sourcing).\nSURPASS members now have access to best-in-class screening solutions, proactive service & relationship-focused support.\nFor more than 30 years, Corporate Screening has served as the background screening provider of choice for the country\'s leading healthcare organizations.
  • "\nSURPASS is a unique collaboration for Premier member health systems, designed to scale purchasing across their systems.
  • Comprising of more than 30,000 acute care beds across 24 states and two U.S. territories, SURPASS member health systems were active participants in this rigorous, 18-month supplier selection process.\nEvery day, the Corporate Screening team pushes to redefine value in background screening.
  • Human intuition and smart automation enable Corporate Screening to exceed expectations with global background screening solutions, criminal background checks, industry-specific searches, continuous monitoring, drug testing and compliance support for the nation\'s top employers.\n'

ViewScan 2.0 from IPVideo Corporation Wins 2021 Govies Government Security Award for Visitor Security Screening

Retrieved on: 
Monday, April 26, 2021

b'BAY SHORE, N.Y., April 26, 2021 /PRNewswire-PRWeb/ -- Security Today magazine recognized the ViewScan 2.0 new features, including user authentication, identification credentialing, and management, as an outstanding government security product for visitor security screening.

Key Points: 
  • b'BAY SHORE, N.Y., April 26, 2021 /PRNewswire-PRWeb/ -- Security Today magazine recognized the ViewScan 2.0 new features, including user authentication, identification credentialing, and management, as an outstanding government security product for visitor security screening.
  • ViewScan 2.0 was chosen for allowing greater government security screening flexibility and faster processing.\nViewScan, the concealed weapons detection, and loss prevention system by IPVideo Corporation , has been updated with version 2.0 allowing for greater flexibility and faster processing with weapons and loss prevention screening.
  • This can be particularly useful for government facilities utilizing ViewScan at events where the system would temporarily need to be placed.
  • IPVideo Corporation leverages artificial intelligence and machine learning through the Internet of Things (IoT) products and professional services.

ViewScan 2.0 from IPVideo Corporation Wins 2021 Secure Campus Award for Best Screening Equipment

Retrieved on: 
Friday, April 23, 2021

b'BAY SHORE, N.Y., April 23, 2021 /PRNewswire-PRWeb/ -- Campus Security & Life Safety magazine recognized ViewScan 2.0\'s new features as an outstanding campus security product announcing it as a 2021 winner of its Secure Campus Awards competition for best screening equipment.

Key Points: 
  • b'BAY SHORE, N.Y., April 23, 2021 /PRNewswire-PRWeb/ -- Campus Security & Life Safety magazine recognized ViewScan 2.0\'s new features as an outstanding campus security product announcing it as a 2021 winner of its Secure Campus Awards competition for best screening equipment.
  • ViewScan was chosen for allowing greater campus security screening flexibility and faster processing.\nViewScan, the concealed weapons detection, and loss prevention system by IPVideo Corporation , has been updated with version 2.0 allowing for greater flexibility and faster processing with weapons and loss prevention screening.
  • This can be particularly useful for utilizing ViewScan at events where the system would temporarily need to be placed.
  • IPVideo Corporation leverages artificial intelligence and machine learning through the Internet of Things (IoT) products and professional services.

Blood Screening Market to Reach $3.56 Billion by 2027, Growing at a CAGR of 6.9% From 2020 With COVID-19 Impact - Meticulous Research® Analysis

Retrieved on: 
Tuesday, April 20, 2021

In 2020, the reagents & kits segment accounted for the largest share of the overall blood screening market.

Key Points: 
  • In 2020, the reagents & kits segment accounted for the largest share of the overall blood screening market.
  • In 2020, the nucleic acid amplification segment accounted for the largest share of the overall blood screening market.
  • In 2020, the blood banks segment accounted for the largest share of the overall blood screening market.
  • In 2020, North America held the largest share of the global blood screening market.

Blood Screening Market to Reach $3.56 Billion by 2027, Growing at a CAGR of 6.9% From 2020 With COVID-19 Impact - Meticulous Research® Analysis

Retrieved on: 
Tuesday, April 20, 2021

In 2020, the reagents & kits segment accounted for the largest share of the overall blood screening market.

Key Points: 
  • In 2020, the reagents & kits segment accounted for the largest share of the overall blood screening market.
  • In 2020, the nucleic acid amplification segment accounted for the largest share of the overall blood screening market.
  • In 2020, the blood banks segment accounted for the largest share of the overall blood screening market.
  • In 2020, North America held the largest share of the global blood screening market.